OOIR: Observatory of International Research

Papers

(The TQCC of Pituitary is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study	93
Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients	44
Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland	37
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas	34
The impact of facility type and volume on treatment and overall survival in craniopharyngioma	30
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency	29
Prevalence and risk factors of colon polyps and other colonic lesions in acromegaly: Insights from colonoscopy screening	27
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies	26
Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours	26
A comparison of macular ganglion cell and retinal nerve fibre layer optical coherence tomographic parameters as predictors of visual outcomes of surgery for pituitary tumours	26
The assessment of thiol-disulfide homeostasis and ıschemia-modified albumin levels in patients with acromegaly	24
Pituitary: hic manebimus optime	24
Genetic models of Cushing’s disease	23
Acromegaly increases depressive symptoms and reduces quality of life of cohabitants	21
Discrimination between non-functioning pituitary adenomas and hypophysitis using machine learning methods based on magnetic resonance imaging‑derived texture features	21
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome	20
Gigantism: microsurgical treatment by transsphenoidal approach and prognostic factors	20
Radiological evolution of autograft fat used for skull base reconstruction after transsphenoidal surgery for pituitary adenomas	20
Machine learning as a clinical decision support tool for patients with acromegaly	19
Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas	19
Functioning gonadotroph adenomas in premenopausal women: clinical and molecular characterization and review of the literature	19
Complications and mortality of Cushing’s disease: report on data collected over a 20-year period at a referral centre	19
ACRODAT and SAGIT for the assessment of disease activity in acromegaly: a multicenter study of the Veneto region in Italy	19
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience	18
Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery	18

Pituitary metastases: a case series and scoping review	18
Predicting tumor consistency and extent of resection in non-functioning pituitary tumors	17
Basal cortisol in relation to metyrapone confirmation in predicting adrenal insufficiency after pituitary surgery	17
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)	16
Diagnosis of growth hormone deficiency: searching for Consensus along life	16
Correction: Development and validation of a novel treatment adherence, satisfaction and knowledge questionnaire (TASK-Q) for adult patients with hypothalamic-pituitary disorders	15
How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing)	15
Commentary: The updated European society of endocrinology clinical practice guideline for the management of aggressive pituitary tumors and pituitary carcinomas	15
The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions	15
TSH-secreting pituitary adenomas and bone	15
Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature	15
A post-hoc internal validation of arginine-stimulated copeptin cut-offs for diagnosing AVP deficiency (central diabetes insipidus)	15
IGF-1 is positively associated with BMI in patients with acromegaly	14
Cushing’s disease and bone	14
Shared decision-making and detection of comorbidities in an online acromegaly consultation with and without the Acromegaly Disease Activity Tool ACRODAT® using the simulated person approach	13
Pituitary metastases from neuroendocrine neoplasms: case report and narrative review	13
Pituitary surgery in Cushing’s disease: first line treatment and role of reoperation	13
Response to letter to the editor “Hypopituitarism and COVID-19, what else?”	13
Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes	13
Generating novel pituitary datasets from open-source imaging data and deep volumetric segmentation	13
Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome	12
Muscle dysfunction is associated with poor quality of life in long-term controlled patients with acromegaly	12
Acromegaly is associated with a distinct oral and gut microbiota	12
Outcomes in surgical management of microprolactinomas: an international multi-institutional series	12
Clinical, surgical, and endocrine outcome following treatment of posterior pituitary tumors: a retrospective cohort study	12
Reappraising prediction of surgical complexity of non-functioning pituitary adenomas after transsphenoidal surgery: the modified TRANSSPHER grade	12
Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas	11
Copeptin after pituitary surgery: is it worth measuring?	11
Pituitary surgery and COVID	11
Long COVID and pituitary dysfunctions: a bidirectional relationship?	11
Is diabetes with acromegaly for life?	11
[68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort	11
Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly	10
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States	10
Characterization of a paradoxical post-operative increase in serum cortisol in Cushing disease	10
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis	10
Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis	10
Demonstration of the inferior intercavernous sinus is closely linked to the extent of pneumatization of the sphenoid sinus: useful information for the pituitary surgeon	10
Surgical treatment of cystic pituitary adenomas: literature-based definitions and postoperative outcomes	10
Hypopituitarism and pregnancy: clinical characteristics, management and pregnancy outcome	10
Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery – a prospective study	10
The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults	10
Serum biomarkers of colonic polyps in patients with acromegaly: a meta-analysis and systematic review	10
Measuring pituitary tumor volume: a comparison of the simplified and non-simplified ellipsoid equation with the 3D planimetric volume assessment	10
Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis	10
Clinical and prognostic implications of pituitary macroadenomas (PitNets) grading: a monocentric experience	10
Refractory nonfunctioning pituitary adenomas	10
Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese	10
Growth hormone insensitivity and adipose tissue: tissue morphology and transcriptome analyses in pigs and humans	9
Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings	9

Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas	9
TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours	9
An update on, and genetics of refractory adenomas of childhood	9
Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists	9
Skeletal fragility in pituitary disease: how can we predict fracture risk?	9
Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence	9
The somatotroph pituitary gland function in high-aged multimorbid hospitalized patients with IGF-I deficiency	9
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma	9
Cushing’s disease: role of preoperative and primary medical therapy	9
High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma	9
Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas	9
Can we predict the risk of venous thromboembolism in patients with Cushing’s syndrome: a nationwide cohort analysis	8
Alert: misinformation that may hurt patients with both adrenal insufficiency and AVP deficiency	8
Clinical use of [18F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants	8
Cushing’s syndrome: Guidance on thromboprophylaxis at last	8
The diagnosis of GH deficiency in adult β-thalassemic patients: are two different stimulation tests necessary to improve specificity?	8
Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis	8
How to manage intolerance to dopamine agonist in patients with prolactinoma	8
The comprehensive evaluation of oral and fecal microbiota in patients with acromegaly	8
Giant prolactinomas, a detailed analysis of 196 adult cases	8
Correction: consensus on criteria for acromegaly diagnosis and remission	8
HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency	8
Idiopathic isolated adrenocorticotropic hormone deficiency: a systematic review of a heterogeneous and underreported disease	8